- GlobeNewswire•7 hours agoFibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
EXTON, Pa., Feb. 23, 2017-- Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the ...
- PR Newswire•yesterday
GERMANTOWN, Md., Feb. 22, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...
- Motley Fool•6 days ago
You can't blame investors who short Intrexon stock.
XON : Summary for Intrexon Corporation Common Sto - Yahoo Finance
Intrexon Corporation (XON)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||21.86 - 22.59|
|52 Week Range||20.39 - 40.24|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-14.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|